Scientists scan brains to unlock secrets of migraine drug
NCT ID NCT04271202
Summary
This study aimed to understand how a migraine prevention drug, galcanezumab (Emgality), works in the brain. Researchers scanned the brains of 64 people with frequent migraines before and after three months of treatment. They looked for changes in brain activity and structure to see if the drug's effects happen inside or outside the brain.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC MIGRAINE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pain Clinic at Beth Israel Deaconess Medical Center
Brookline, Massachusetts, 02445, United States
Conditions
Explore the condition pages connected to this study.